Sitoe Nádia, Chelene Imelda, Ligeiro Sofia, Castiano Celso, Ahmed Mohamed I M, Held Kathrin, Nhassengo Pedroso, Khosa Celso, Matavele-Chissumba Raquel, Hoelscher Michael, Rachow Andrea, Geldmacher Christof
Instituto Nacional de Saúde, Marracuene 3943, Mozambique.
CIH LMU Center for International Health, Ludwig-Maximilians University, 80802 Munich, Germany.
Pathogens. 2023 Jun 1;12(6):794. doi: 10.3390/pathogens12060794.
The mycobacteriological analysis of sputum samples is the gold standard for tuberculosis diagnosis and treatment monitoring. However, sputum production can be challenging after the initiation of TB treatment. As a possible alternative, we therefore investigated the dynamics of neutrophil-derived soluble inflammatory mediators during TB treatment in relation to HIV ART status and the severity of lung impairment. Plasma samples of TB patients with (N = 47) and without HIV (N = 21) were analyzed at baseline, month 2, month 6 (end of TB treatment) and month 12. Plasma levels of MMP-1, MMP-8, MPO and S100A8 markedly decreased over the course of TB treatment and remained at similar levels thereafter. Post-TB treatment initiation, significantly elevated plasma levels of MMP-8 were detected in TB patients living with HIV, especially if they were not receiving ART treatment at baseline. Our data confirm that the plasma levels of neutrophil-based biomarkers can be used as candidate surrogate markers for TB treatment outcome and HIV-infection influenced MMP-8 and S100A8 levels. Future studies to validate our results and to understand the dynamics of neutrophils-based biomarkers post-TB treatment are needed.
痰液样本的分枝杆菌学分析是结核病诊断和治疗监测的金标准。然而,在开始结核病治疗后,咳痰可能具有挑战性。因此,作为一种可能的替代方法,我们研究了结核病治疗期间中性粒细胞衍生的可溶性炎症介质的动态变化,及其与HIV抗逆转录病毒治疗状态和肺损伤严重程度的关系。在基线、第2个月、第6个月(结核病治疗结束时)和第12个月对47例合并HIV的结核病患者和21例未合并HIV的结核病患者的血浆样本进行了分析。在结核病治疗过程中,MMP-1、MMP-8、MPO和S100A8的血浆水平显著下降,此后维持在相似水平。在开始结核病治疗后,在合并HIV的结核病患者中检测到MMP-8的血浆水平显著升高,尤其是那些在基线时未接受抗逆转录病毒治疗的患者。我们的数据证实,基于中性粒细胞的生物标志物的血浆水平可作为结核病治疗结果的候选替代标志物,并且HIV感染会影响MMP-8和S100A8水平。需要开展进一步研究以验证我们的结果,并了解结核病治疗后基于中性粒细胞的生物标志物的动态变化。